Citigroup
CADX

Citigroup’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Citigroup’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-13,052
Closed -$183K – 7632
2014
Q1 		$183K Sell
13,052
-19,577
-60% -$242K ﹤0.01% 4417
2013
Q4 		$296K Buy
32,629
+12,079
+59% +$87.2K ﹤0.01% 4292
2013
Q3 		$130K Sell
20,550
-227
-1% -$1.44K ﹤0.01% 4520
2013
Q2 		$143K Buy
+20,777
New +$145K ﹤0.01% 4554

Citigroup's CADX Position: Q2 2014 in Review

Citigroup sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q2 2014, closing a stake of 13,052 shares — an estimated $183K sold.

Citigroup first reported a position in CADX in Q2 2013 and held it in 4 quarters. The position peaked at $296K in Q4 2013. 0 funds tracked by Wall St. Rank hold CADX as of Q2 2014.

  • Citigroup reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q2 2014 after selling out during the quarter.
  • Citigroup sold 13,052 CADENCE PHARMACEUTICALS, INC COM STK shares in Q2 2014, an estimated $183K.
  • Citigroup first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 4 quarters.
  • Citigroup's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $296K in Q4 2013.
  • 0 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q2 2014.

Based on Citigroup's 13F filing for Q2 2014, filed 14 Aug 2014.